Stay updated on PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC
Sign up to get notified when there's something new on the PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC page.

Latest updates to the PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC page
- Check7 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference5%
- Check14 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check21 days agoNo Change Detected
- Check29 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check36 days agoChange DetectedThe website has updated the intervention details to include a verified status by Jiangsu HengRui Medicine Co., Ltd. and has upgraded to revision v2.14.0, while the previous type of intervention and revision v2.13.3 have been removed.SummaryDifference3%
- Check65 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.3%
- Check72 days agoChange DetectedThe website has been updated from version v2.12.2 to v2.13.2, indicating a new release with potential improvements or features.SummaryDifference0.3%
Stay in the know with updates to PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC
Enter your email address, and we'll notify you when there's something new on the PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC page.